You’ve made it through four weeks of twice-weekly visits, arranged rides, and sat through two-hour monitoring periods, and you still feel depressed. That can be a painfully lonely moment. If Spravato has helped only a little, or not at all, it does not mean you didn’t try hard enough. A partial or absent response is information for your care team, not a verdict on you.
At Light-tunnel Behavioral Health Services Inc. in New Haven, Dr. Omolola Aragbada, PMHNP-BC, is one of the psychiatric providers who can help review your response and discuss what comes next. Earlier this week, our Monday post covered eligibility and the two FDA-approved uses of esketamine, and Wednesday’s post walked through the treatment schedule; here, we’ll focus on what happens when the response is incomplete or fades.
What does “working” mean clinically?
Clinicians may describe response as a substantial improvement, often a reduction of at least 50% on a depression rating scale, and remission as symptoms falling below a scale’s threshold for clinically significant depression. The exact measure and threshold vary.
Your experience is more than a score, though. Sleep, energy, concentration, daily functioning, and interest in people or activities all matter. Sometimes the first change is not a bright day; it’s a shorter low, a slightly easier morning, or one task that takes less effort. Think of a dimmer switch, not an on/off light: improvement can happen by degrees.

The four-week checkpoint
For treatment-resistant depression, the FDA prescribing information directs clinicians to assess evidence of benefit at the end of the four-week induction phase before deciding whether to continue. It allows a clinician to adjust between 56 mg and 84 mg based on benefit and tolerability.[^1] Never change your dose or schedule on your own. Your prescriber should make any adjustment after reviewing your symptoms, side effects, and medical history.
Three response patterns, and what a clinician may review
| Partial response | No response | Response that later fades |
|---|---|---|
| What it may look like: Some relief, such as improved sleep or shorter periods of intense sadness, while major symptoms remain. | What it may look like: Little or no meaningful change in symptoms or day-to-day functioning. | What it may look like: You felt better for a time, then symptoms returned or began to intensify. |
| What your clinician may review: Dose, schedule, missed sessions, oral antidepressant, side effects, sleep, alcohol or substance use, thyroid or other medical factors, and therapy engagement. | What your clinician may review: The same factors, including whether missed sessions or another health issue could be affecting the picture. | What your clinician may review: The same factors, plus when symptoms returned, changes in life circumstances, and whether the maintenance plan needs reassessment. |
| Realistic next step: Discuss whether continuing with a clinician-directed adjustment or adding another treatment makes sense. | Realistic next step: Revisit the diagnosis and treatment plan together; consider other depression treatment options rather than assuming there is no path forward. | Realistic next step: Contact your care team promptly to review the pattern and discuss a safe plan. Don’t restart or change treatment by yourself. |
This review is collaborative, not a test you can fail. If you’re unsure what was decided, ask your clinician to explain the plan in plain language and put the next steps in writing.
What the research can, and can’t, tell you
In the open-label, active-controlled ESCAPE-TRD randomized trial, remission at week 8 occurred in 27.1% of participants taking esketamine nasal spray with an ongoing SSRI or SNRI, compared with 17.6% taking extended-release quetiapine with an antidepressant (Reif et al., 2023).[^2] That is a meaningful difference, while also showing that most participants in both groups had not reached remission at week 8. The study was conducted outside the United States, and its open-label design is an important limitation.
SUSTAIN-1 studied a different question: relapse prevention among people who had already achieved stable remission. Among those participants, relapse occurred in 26.7% who continued esketamine and 45.3% who switched to placebo nasal spray while continuing their oral antidepressant (Daly et al., 2019).[^3] Because only people who had already responded entered the randomized-withdrawal phase, those numbers cannot predict your personal timeline or likelihood of benefit.

If it hasn’t worked, what are the actual next options?
These are different tools with different tradeoffs, not a ranking. The right choice depends on your history, health, response pattern, preferences, and life logistics.
| Option | How it is given and schedule | Evidence base | Practical burden | Who it may suit |
|---|---|---|---|---|
| Continue or adjust Spravato | Nasal treatment at a certified clinic; schedule and dose are set by your clinician. | FDA labeling calls for a benefit review after the four-week induction phase for treatment-resistant depression.[^1] | Clinic visits, observation after dosing, and arranging transportation; no driving until the next day after restful sleep, per prescribing instructions. | Someone with some benefit, or for whom the clinician believes a monitored adjustment or continuation is appropriate. |
| Different oral augmentation strategy | A prescribed oral medicine, generally taken daily, with follow-up visits for assessment and adjustment. | Options vary; suitability depends on prior medicines, symptoms, health conditions, and side-effect considerations. | Daily medication and periodic follow-up; side effects and interactions require monitoring. | Someone who wants to consider a medication-based next step or revisit an existing medication plan. |
| TMS, including BrainsWay Deep TMS with an H1 coil | Noninvasive magnetic stimulation, commonly on weekdays over several weeks. In a pivotal H1-coil study, 18 Hz Deep TMS was given for 20 sessions over four weeks (Levkovitz et al., 2015).[^4] | Deep TMS is among the more researched TMS systems; the H1 coil has been studied in large randomized, sham-controlled trials. A network meta-analysis of 81 randomized trials found high-frequency rTMS over the left dorsolateral prefrontal cortex more likely than sham to produce response (odds ratio about 3.07); that pooled finding is not specific to every TMS device or protocol (Brunoni et al., 2017).[^5] | Sessions are often about 20–40 minutes, depending on system and settings; some protocols are around 3 minutes. No anesthesia or required recovery time, so many people can drive afterward. The near-weekday visits can be demanding. | Someone seeking a nonmedication option who can manage frequent visits and is medically appropriate for treatment. |
| IV ketamine | Infusion in a supervised setting; protocols differ. In ELEKT-D, the course was twice weekly for three weeks. | In a randomized trial of 403 adults with nonpsychotic treatment-resistant depression, response was 55.4% with IV ketamine versus 41.2% with ECT over three weeks; ketamine was noninferior to ECT in that trial (Anand et al., 2023).[^6] | Repeated visits and monitoring; transportation may be needed after treatment. IV ketamine is distinct from FDA-approved esketamine nasal spray. | Someone whose clinician considers this approach appropriate and who can access a supervised treatment setting. |
| ECT | Treatment under anesthesia, often multiple times weekly during an acute course; the specific plan varies. | In ELEKT-D, ECT was an active comparator. The trial also found a temporary decline in delayed memory recall in the ECT group (Anand et al., 2023).[^6] | Anesthesia, recovery time, transportation, and frequent visits; memory effects and other risks need discussion with the treating team. | Someone whose clinical needs and preferences make ECT a reasonable option after specialist assessment. |
| More intensive psychotherapy | More frequent individual therapy, a different therapy approach, or coordinated therapy alongside other care. | Psychotherapy approaches such as CBT and DBT are offered as part of individualized mental health care; the right fit depends on your needs and goals. | Regular appointments and between-session practice; frequency and format vary. | Someone who wants additional support for coping skills, behavior patterns, relationships, or the stressors that accompany depression. |
For people looking for Transcranial Magnetic Stimulation in New Haven or TMS treatment in New Haven, an evaluation can help clarify whether it is a suitable option; treatment choices should be made with a qualified clinician, not from a table alone. You can read more about TMS therapy for treatment-resistant depression and OCD and about the practice's other services.
A quick myth check about the observation period
Feeling spacey or “floaty” during Spravato’s two-hour observation window does not mean the medication is working. And feeling no unusual effects does not mean it isn’t. Dissociation during dosing is a monitored side effect, not a measure of benefit.
While you’re waiting for your next appointment
Do:
- Track sleep and daily functioning in a few lines each day.
- Bring the actual dates of any missed sessions.
- Tell your care team about alcohol or cannabis use and any new medications.
- Ask for the plan in writing, including when to follow up.
Avoid:
- Stopping treatment or changing doses on your own.
- Judging the whole treatment by one especially difficult week.
- Adding supplements or stimulants without telling your prescriber.
- Treating a crisis line as a substitute for emergency care when there is immediate danger.
Care options, including self-pay
Self-pay clients can ask about a psychiatric evaluation, medication management for depression, therapy, and TMS. Request an itemized estimate for evaluation and follow-up costs before starting, and ask about any other expected charges. Light-tunnel Behavioral Health Services Inc. accepts a range of major insurance plans, though coverage and authorization vary by plan. You can contact the practice with questions or request an in-person appointment.

Medical safety and crisis support
This article is for general education and is not a substitute for medical advice, diagnosis, or treatment. Talk with your prescriber before making treatment decisions. If you’re in emotional distress or having thoughts of suicide, call or text 988 to reach the Suicide & Crisis Lifeline. If you or someone else is in immediate danger, call 911 or go to the nearest emergency department, do not wait for a routine appointment.
References
- U.S. Food and Drug Administration. Spravato (esketamine) nasal spray: Prescribing Information. DailyMed, National Library of Medicine. Full prescribing information.
- Reif A, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med. 2023;389:1298–1309. PubMed.
- Daly EJ, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry. 2019. PubMed.
- Levkovitz Y, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14(1):64–73. PubMed.
- Brunoni AR, et al. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry. 2017. PubMed.
- Anand A, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023;388:2315–2325. PubMed.
Continue the Series
Read Monday’s post on Spravato eligibility, the REMS program, and the two FDA-approved uses of esketamine in New Haven.